ViaCyte Overview
- Founded
- 1999
- Status
- Private
- Employees
- 95
- Latest Deal Type
- 2ndary - Private
- Investors
- 28
ViaCyte General Information
Description
Operator of a regenerative medicine company intended to discover, develop and commercialize novel cell replacement therapies to treat human diseases. The company's therapies are based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device, enabling healthcare institutions to reduce diabetes-related complications efficiently.
Contact Information
Website
Formerly Known As
Novocell, CyThera
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 3550 General Atomics Court
- San Diego, CA 92121
- United States
+1 (858) 000-0000
ViaCyte Timeline
ViaCyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 24. Secondary Transaction - Private | 00000 | Completed | Clinical Trials - General | |||
| 23. Later Stage VC (Series D) | 26-May-2020 | 0000 | 00000 | 00000 | Completed | Clinical Trials - General |
| 22. Corporate | 25-Sep-2018 | 0000 | 00000 | Completed | Clinical Trials - General | |
| 21. Grant | 17-Apr-2018 | 00.00 | 00000 | Completed | Clinical Trials - General | |
| 20. Grant | 15-Dec-2017 | 00.00 | 00000 | Completed | Clinical Trials - General | |
| 19. Later Stage VC | 22-May-2017 | 0000 | 00000 | Completed | Clinical Trials - General | |
| 18. Grant | 01-Jan-2017 | 000.00 | 00000 | Completed | Clinical Trials - General | |
| 17. Grant | 11-Sep-2014 | 000.00 | 00000 | Completed | Clinical Trials - General | |
| 16. Later Stage VC (Series C1) | 17-Jul-2013 | $16.5M | $104M | Completed | Clinical Trials - General | |
| 15. Grant | 26-Oct-2012 | $10.1M | $87.1M | Completed | Clinical Trials - General |
ViaCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D2 | 000,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series D1 | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series D-IA | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
| Series C | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
| Series B | 27,876,992 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 3.93% |
| Series A | 8,020,005 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 1.13% |
ViaCyte Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a regenerative medicine company intended to discover, develop and commercialize novel cell replacement thera
Drug Discovery
San Diego, CA
95
As of 2020
00000
000000 - 000
00000
00000 00
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqu
0000 000000000
Cambridge, MA
00000
0000
0000-00-00
000000&0
00000
00000000
in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat no
0000 000000000
South San Francisco, CA
00
As of 0000
00000
0000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialViaCyte Competitors (30)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Semma Therapeutics | Formerly VC-backed | Cambridge, MA | 00000 | 000000&0 | 00000 | |
| 00000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 0000000000 | 00000 |
| 000000 000000000 | Formerly PE-Backed | Germantown, MD | 0 | 000.00 | 000000&0 | 000.00 |
| 000000000 | Formerly VC-backed | Tucson, AZ | 00 | 000.00 | 000000&0 | 000.00 |
| 0000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
ViaCyte Executive Team (15)
ViaCyte Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Koppel MD | Bain Capital | Board Member | 000 0000 |
| Asish Xavier Ph.D | Self | Board Member | 000 0000 |
| Fred Middleton | Sanderling Ventures | Board Member | 000 0000 |
| Heath Lukatch Ph.D | TPG Biotech | Board Member | 000 0000 |
| Ian Smith | Self | Executive Chairman | 000 0000 |
ViaCyte Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialViaCyte Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bain Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| RA Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
| TPG Biotech | Venture Capital | Minority | 000 0000 | 000000 0 | |
| CRISPR Therapeutics | Corporation | Minority | 000 0000 | 000000 0 | |
| The National Institute of Diabetes and Digestive and Kidney Diseases | Government | 000 0000 | 000000 0 |
ViaCyte Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 (000000000 | 18-Dec-2015 | 000000000000000000 | Biotechnology | 0000 0000000 00.0 |